<DOC>
	<DOCNO>NCT01035138</DOCNO>
	<brief_summary>The primary objective original study assess safety semagacestat Alzheimer 's disease ( AD ) patient 24 month open-label treatment . Baseline efficacy measure define baseline feeder study LFAN ( NCT00594568 ) LFBC ( NCT00762411 ) . For safety analysis ( adverse event ) , baseline patient week 0 study ( LFBF ) . Preliminary result LFAN LFBC show semagacestat slow disease progression associate worsen clinical measure cognition ability perform activity daily live . Study drug stop study . Studies LFAN , LFBC LFBF amend continue collect safety data , include cognitive score , least seven month . The CT-Registry reflect result analyse original protocol addition amend protocol . Very participant LFBC roll LFBF ( N = 9 ) . Due insufficient sample size , data LFBC participant roll LFBF analyze .</brief_summary>
	<brief_title>A Study Semagacestat Alzheimer 's Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Meets National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable Alzheimer 's Disease Completed semagacestat study LFAN study LFBC 88 week Must continue reliable caregiver Capable swallow whole oral medication Agrees participate investigational compound duration study Meets LFAN LFBC study discontinuation criterion last visit LFAN LFBC study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>